DURHAM, N.C., May 23, 2018 /PRNewswire/ — A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers and clinicians held […]
Tag: MiCell
Micell Technologies’ Positive Five-Year Data Published for MiStent in EuroIntervention
DURHAM, N.C., Jan. 9, 2018 /PRNewswire/ — Micell Technologies announced the recent online publication of five-year data from the DESSOLVE I and II trials. The report, “Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year […]
The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience®
DURHAM, N.C., Dec. 6, 2017 /PRNewswire/ — Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting […]
MiCell Has significant raise for MiStent
Micell raises $62m for MiStent SES SEPTEMBER 19, 2017 BY BRAD PERRIELLO, Drug Delivery Business News Micell Technologies said last week that it raised a debt-and-equity round worth nearly $62 million from a syndicate of 51 unnamed investors. Paris-based Micell makes the MiStent SES […]